Commodore Capital
Venture capitalNew York · Series C–Late Stage · 16 people tracked
Find your way into Commodore Capital
1,698 people in our graph share verified history with the Commodore Capital team — schools, employers, funds. One of them is your warm intro.
Investment thesis
Commodore Capital believes the biopharmaceutical industry is in the early stages of a major innovation cycle, driven by scientific discoveries translating into clinical breakthroughs through novel therapeutic modalities such as genetic medicines and cellular therapies. The firm notes that innovation has shifted from large pharmaceutical companies to smaller biopharmaceutical firms. Commodore aims to be a supportive partner to these companies as they work to bring safe and effective new medicines to patients worldwide.
Source: firm website, verified Sep 29, 2026.
What founders say
No founder feedback on Commodore Capital yet.
Team · 16 people
from the firm's website & curated & public directoriesWhat they invest in
from 12 of 12 portfolio companiesBiotech ×7AI & Machine Learning ×2Enterprise Software ×2Healthtech ×2SaaS ×2Consumer ×1Crypto & Web3 ×1Deep Tech ×1
HQs:United States×7Finland×1Indonesia×1Portugal×1
Investments · 12 tracked
founders shown can be your intro pathBy year:2026 · 32025 · 22024 · 12021 · 32020 · 110 dated
Agenus is a biotechnology company developing cancer immunotherapies, including its lead investigational combination of botensilimab (an anti-CTLA-4 antibody) and balstilimab (a PD-1 inhibitor), known as BOT+BAL.
BiotechHealthtechLexington, US
Garo Armen(Chairman & CEO, Co-founder)Ozer Baysal(Executive Officer)Robert Stein(Executive Officer)Christine Klaskin(Executive Officer)inKaren Valentine(Executive Officer)Steven O'Day(Chief Medical Officer)in
Co-investorsAdvent Life SciencesGrazia Equity GmbHHEALTHCARE ROYALTY PARTNERSOberland CapitalInvusLigand Pharmaceuticals+1 more
Damora Therapeutics is a preclinical-stage biotechnology company that discovers and develops therapeutic candidates, including DMR-001, DMR-002, and DMR-003, with the goal of advancing treatments through investigational drug applications and clinical trials.
BiotechCopenhagen, US
Garrett Winslow(Executive Officer)inLori Firmani(Executive Officer)inHans T. Schambye(Executive Officer, Director)Jennifer Jarrett(President, Chief Executive Officer and Director)inBecker Hewes(Chief Medical Officer)Sherwin Sattarzadeh(Chief Operating Officer)
Co-investorsAccess BiotechnologyAndreessen HorowitzBAM ElevateBay City CapitalEIR VenturesForbion+7 more
Relmada is a clinical-stage biopharmaceutical company developing therapies including NDV-01, a sustained-release intravesical formulation of gemcitabine and docetaxel for non-muscle invasive bladder cancer, and Sepranolone, a candidate targeting compulsive behaviors via GABAA receptor modulation.
BiotechHealthtechNew York, US
Sergio Traversa(Executive Officer, Director)Paul Kelly(Director)Maged Shenouda(Director)inEliseo O. Salinas(President and Chief Scientific Officer)inDouglas Beck(Chief Financial Officer)Charles Ence(Chief Accounting and Compliance Officer)
Co-investorsBioAdvanceBAM ElevateBraidwellJanus Henderson InvestorsOrbiMedRA Capital+2 more
AirHelp provides technology to help air passengers claim compensation for delayed and cancelled flights.
ConsumerLegalTechSaaSTravel & HospitalityLisbon, PT
Henrik Zillmer(Founder)inNicolas Michaelsen(Founder)inGreg Roodt(Founder/CTO)inTomasz Pawliszyn(CEO)in
Co-investorsABRY PartnersTempoCapUpslope VenturesY Combinator10x Founders10x Group+11 more
A biotechnology company developing new therapies for patients with high unmet medical needs.
Biotech
Co-investorsDolby Family VenturesLifeSci Venture PartnersSofinnova VenturesThe W FundFranklin TempletonLigand Pharmaceuticals+5 more
IDRX is a regulated stablecoin backed 1:1 by the Indonesian Rupiah, letting users hold and transfer IDR value on blockchain networks for payments, trading, and Web3 financial activity.
Crypto & Web3Fintech
Co-investorsMDI VenturesRA Capital
BiotechNew York, US
Norbert Bischofberger, Ph.D.(Executive Officer, Director)Christopher Wilfong(Executive Officer)
BoardRebecka Belldegrun, M.D.(Director)Otello Stampacchia, Ph.D.(Director)David M. Tanen(Executive Officer, Director, Promoter)Arie S. Belldegrun, M.D.(Director)
Co-investorsEcoR1 CapitalGV (Google Ventures)Nextech InvestVida VenturesBlackRockInvus+2 more
Nimbus develops wireless power technology that uses invisible infrared LED light to transmit energy across a room, with a receiver that converts the light into electricity to charge laptops, phones, and other devices.
Deep TechEnergyHardware
Michael Gorman(Founder)in
Co-investorsFoothill VenturesAccess BiotechnologyAtlas VentureBain Capital Life SciencesBiotechnology Value FundGV (Google Ventures)+2 more
FuseBase is an enterprise platform for deploying and managing AI agents across teams with role-based access controls, audit trails, and integrations to CRM, Slack, Teams, and email systems.
AI & Machine LearningEnterprise SoftwareFuture of WorkSaaSCleveland, US
Pavel Sher(CEO)Aaron Adsit(CRO)Denis Kibalko(CTO)
Co-investorsPre-Seed to SucceedYellow Rocks!Access BiotechnologyAtlas VentureBain Capital Life SciencesBiotechnology Value Fund+3 more
Speechly provides an API that performs speech recognition and language understanding directly on user devices, reducing costs for applications that need to analyze spoken interactions in real time.
AI & Machine LearningDeveloper ToolsEnterprise SoftwareHelsinki, FI
Otto Soderlund(Founder)inHannes Heikinheimo(Founder)in
Co-investorsCherry VenturesSNÖ VenturesTq Ventures LlcY Combinator10X CapitalAtypical Ventures+6 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Exits · 4
3 IPOs · 1 acquisitionsAgenusNASDAQ: AGENDamora TherapeuticsNASDAQ: DMRARelmada TherapeuticsNASDAQ: RLMDSpeechlyacq. by Roblox
Portfolio news
latest coverage across their companiesAgenus · simplywall.st · Aug 15, 2026
Athira · geekwire.com · Dec 18, 2025
Frequently asked questions
- How many investments has Commodore Capital made?
- Commodore Capital has 12 tracked investments, 4 of which have exited, including 5 dated in the last 24 months.
- What stage does Commodore Capital invest at?
- Commodore Capital invests at the Series C, Late Stage stages.
- What sectors does Commodore Capital focus on?
- Commodore Capital focuses on Biotech.
- Where is Commodore Capital located?
- Commodore Capital is headquartered in New York, US.
- Does Commodore Capital lead rounds?
- Commodore Capital typically participates in rounds rather than leading them.
Similar investors
Amadeus Capital Partners is a UK-based deep tech venture capital firm founded in 1997 that invests in technology companies from seed to growth stage. Since inception it has backed over 200 companies and raised more than $1.3 billion.
Capricorn Partners is a Belgium-based, partner-owned independent management company for alternative investment funds, investing in innovative companies across digital, health and clean technologies with an ESG focus.
New Enterprise Associates (NEA) is a venture capital firm that invests in and provides long-term support to founders building new companies.
Summit Partners is a growth equity investment firm that partners with management teams across technology, healthcare & life sciences, and growth products & services sectors to build long-term value.
























































